LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

LLY

981.8

-1.41%↓

JNJ

199.89

-0.85%↓

ABBV

222.81

-0.04%↓

UNH

323.54

+0.12%↑

AZN

89.56

-1.8%↓

Home・Akcijų sąrašas・Axsome Therapeutics Inc

Axsome Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

145.13 -1.66

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

143.51

Max

147.61

Pagrindiniai rodikliai
By Trading Economics
Pajamos	744K -47M
Pardavimai	21M 171M
Pelnas, tenkantis vienai akcijai	-0.94
Pelno marža	-27.621
Darbuotojai	816
EBITDA	-7.7M -44M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+18.77% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	718M 7.4B
Ankstesnė atidarymo kaina	146.79
Ankstesnė uždarymo kaina	145.13

Naujienos nuotaikos

By Acuity

12%

88%

13 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

107.24 / 112.29 Palaikymas ir pasipriešinimas

Axsome Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-09 22:13; UTC

Uždarbis

GE Vernova Raises Outlook, Doubles Dividend on Energy Market Momentum

2025-12-09 21:40; UTC

Uždarbis

GameStop Sales Fall as Collectibles Remain Only Bright Spot

2025-12-09 18:51; UTC

Įsigijimai, susijungimai, perėmimai

Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical

2025-12-09 16:57; UTC

Pagrindinės rinkos jėgos

Clear Secure Rises on Medicare Identity Verification Contract

2025-12-09 23:46; UTC

Rinkos pokalbiai

Nikkei May Trade Rangebound Ahead of Fed Rate Decision -- Market Talk

2025-12-09 23:46; UTC

Įsigijimai, susijungimai, perėmimai

Legend Holdings Stake in Lenovo Now at 32.34%

2025-12-09 23:45; UTC

Įsigijimai, susijungimai, perėmimai

Legend Holdings: Remains Optimistic About Lenovo's Future Development Potential

2025-12-09 23:44; UTC

Įsigijimai, susijungimai, perėmimai

Legend Holdings: Purchased Lenovo Shares at Average Price of HK$9.7653/Share

2025-12-09 23:43; UTC

Įsigijimai, susijungimai, perėmimai

Legend Holdings: Acquired Lenovo Shares for Total Cash Consideration of HK$1.12B

2025-12-09 23:43; UTC

Įsigijimai, susijungimai, perėmimai

Legend Holdings: Acquired 115.17M Lenovo Shares From Open Market Between Nov. 21 and Dec. 9

2025-12-09 23:35; UTC

Rinkos pokalbiai

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

2025-12-09 22:42; UTC

Uždarbis

PepsiCo Wants to Boost Sales, Cut Costs. The Street Is Doubtful. -- Barrons.com

2025-12-09 21:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-12-09 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-09 21:48; UTC

Rinkos pokalbiai

Hiring Confidence Slips in Canada Entering 2026 -- Market Talk

2025-12-09 21:36; UTC

Uždarbis

Casey's General Stores: Fiscal 2026 EBITDA Is Expected to Increase 15% to 17% >CASY

2025-12-09 21:36; UTC

Uždarbis

Casey's General Stores: Total Inside Gross Profit Increased 13.5% to $703.4M Compared to Prior Yr >CASY

2025-12-09 21:36; UTC

Uždarbis

Casey's General Stores: Now Expects Inside Same-Store Sales to Increase 3% to 4% and an Inside Margin of 41% to 42% >CASY

2025-12-09 21:36; UTC

Uždarbis

Casey's General Stores: Same-Store Fuel Gallons Up 0.8% Compared to Prior Yr With Fuel Margin of 41.6 Cents per Gallon, Total Fuel Gross Profit Increased 20.9% to $377.4M Compared to Prior Yr >CASY

2025-12-09 21:36; UTC

Uždarbis

Casey's General Stores: Inside Same-Store Sales Increased 3.3% Compared to Prior Yr, and 7.5% on 2-Yr Stack Basis, With an Inside Margin of 42.4% >CASY

2025-12-09 20:28; UTC

Rinkos pokalbiai

Oil Futures Decline for Second Straight Session -- Market Talk

2025-12-09 20:27; UTC

Įsigijimai, susijungimai, perėmimai

Teck Resources: Merger of Equals With Anglo Amer Plc Approved by Both Classes of Teck Hldrs

2025-12-09 20:27; UTC

Įsigijimai, susijungimai, perėmimai

Teck Reports Voting Results From Special Meeting of Hldrs

2025-12-09 20:26; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Moody's: Paramount's Warner Bid Makes Strategic Sense, With Risk -- Market Talk

2025-12-09 20:21; UTC

Rinkos pokalbiai

U.S. Natural Gas Extends Pullback on Shifting Weather Outlook -- Market Talk

2025-12-09 19:52; UTC

Uždarbis

Correction to 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com on Dec. 8

2025-12-09 19:17; UTC

Uždarbis

Update: 58 S&P 500 Stocks Have Dividends Higher Than Treasuries. 10 Look Better Than Bonds. -- Barrons.com

2025-12-09 17:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-09 17:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-12-09 17:11; UTC

Uždarbis

Nvidia Has Permission to Sell H200 Chips to China. Why It Might Not Matter Much for the Stock. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Axsome Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

18.77% į viršų

12 mėnesių prognozė

Vidutinis 175.25 USD 18.77%

Aukščiausias 202 USD

Žemiausias 148 USD

Remiantis 15 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Axsome Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

15 ratings

Pirkti

Laikyti

Parduoti

Remiantis 15 analitikų, pateikusių Axsome Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

107.24 / 112.29Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bullish.

Rinkos nuotaikos

By Acuity

13 / 374 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.